With Eylea in decline, Regeneron awaits FDA approval for higher dose of blockbuster
Regeneron is banking on getting a higher dose of aflibercept, the Bayer-partnered wet AMD drug also known as Eylea, to the US market as soon …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
